The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis

Arquivos de Gastroenterologia

Volumn 47, Issue 1, 2010, Pages 86-92

  Zamin Jr , Idilio ^a   De Mattos, Angelo Alves ^a   De Mattos, Ângelo Zambam ^a   Coral, Gabriela ^a   Santos, Diogo ^a   Rhoden, Cláudia ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Fatty liver; Rats; Vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CHOLINE; METFORMIN; METHIONINE; SIMVASTATIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIOXIDANTS; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; FATTY LIVER; HYPOLIPIDEMIC AGENTS; LIPID PEROXIDATION; MALE; METFORMIN; METHIONINE; PROSPECTIVE STUDIES; RATS; RATS, WISTAR; SIMVASTATIN; TRANSAMINASES; VITAMIN E;

EID: 77953199489     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032010000100015     Document Type: Article

References (46)

1. Angulo P. Nonalcoholic fatty liver disease [medical progress]. N Engl J Med. 2002;346:1221-1231 (Pubitemid 34984585)
2. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an explanded clinical entity. Gastroenterology. 1994;107:1103-1109
3. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140 (Pubitemid 34747534)
5. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformina versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1082-1090 (Pubitemid 40769045)
6. Byron D, Minuk G. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology. 1996;24:813-815 (Pubitemid 26334278)
7. Caldwell SH, Oelsner DH, Iezzoni JC. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669 (Pubitemid 29109578)
8. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056-1062
9. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-1654
10. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:83-88 (Pubitemid 16041850)
11. Grattagliano I, Vendemiale G, Caraceni P, Domenicali M, Nardo B, Cavallari A, Trevisani F, Bernardi M, Altomare E. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr. 2000;130:2131-2136
12. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490 (Pubitemid 37448761)
13. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2004;8:861-879 (Pubitemid 39311147)
14. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001;15:1667-1672 (Pubitemid 32912411)
15. Horlander JC, Kwo P Y, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH. Gastroenterology. 2001;120:A544.
16. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713-718 (Pubitemid 38072335)
17. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419 (Pubitemid 36919862)
18. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734-738 (Pubitemid 30415645)
19. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075 (Pubitemid 30217691)
20. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275
22. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438
23. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-894
24. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19:205-219
25. Nair S, Wiseman M. HMG-CoA reductase inhibitors in non alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology. Hepatology. 2002;36:A409.
26. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23-28 (Pubitemid 38938715)
27. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligant rosiglitazone. Hepatology. 2003;38:1008-1017 (Pubitemid 37221684)
28. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn. 1992;27:521-528
29. Okan A, Astarcioglu H, Tankurt E, Sagol O, Altekin E, Astarcioglu I, Gonen O. Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig Dis Sci. 2002;47:2389-2397 (Pubitemid 35305441)
30. Palmer M, Schaffener F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-1413 (Pubitemid 20381878)
31. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver. FEBS. 1992;308:267-270
32. Phung N, Farrell G, Robertson G, George J, Westmead Millennium Inst at Westmead Hosp, Univ of Sydney, Sydney Australia. Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology. 2001;34:A361.
33. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80. (Pubitemid 20075105)
34. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196 (Pubitemid 38461481)
35. Rogers AE, Newberne PM. Alcoholic and nutritional fatty liver and cirrhosis. Am J Pathol. 1973;73:817-820
36. Schaffner F, Adler M. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67:811-816 (Pubitemid 10218835)
37. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8: 283-288
38. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformina as a treatment for non-diabetic pediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871-879 (Pubitemid 40477247)
39. Teli MR, James OF, Burt AD, Bennett MK, Day C P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719
40. Ueno T, Sugawara H, Sujako K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103-107 (Pubitemid 27357062)
41. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537-544 (Pubitemid 38387180)
42. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48-55. (Pubitemid 39274467)
43. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-1110
44. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;111:1645-1653 (Pubitemid 26404230)
45. Younossi Z, Diehl AM, Ong J P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-752 (Pubitemid 34258367)
46. Zamin IJ, Mattos AA, Zettler CG. Non-alcoholic steatohepatitis in nondiabetic obese patients. Can J Gastroenterol. 2002;16:303-308